An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer

Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets the human trophoblast cell-surface antigen 2 to deliver SN-38 to cancer cells. In this study, we assessed the efficacy and safety of SG in patients with relapsed or refractory metastatic triple-negative breast cancer (RM-TNBC). ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Shao-Xian, Chen, Qiu-Chi, Lin, Guo-He, Han, Yan-Hong, Wang, Bi-Cheng, Dai, Yi, Zhao, Yan-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article: Systematic Review and Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378904/
https://www.ncbi.nlm.nih.gov/pubmed/37505137
http://dx.doi.org/10.1097/MD.0000000000034486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378904/
https://www.ncbi.nlm.nih.gov/pubmed/37505137
http://dx.doi.org/10.1097/MD.0000000000034486

Ejemplares similares